Stealth and Fully-Laden Drug Carriers: Self-Assembled Nanogels Encapsulated with EGCG and siRNA (2018)
Sequence: cCPGPEGAGC-LLIILRRRIRKQAHAHSK-NH2
| Experiment Id | EXP002353 |
|---|---|
| Paper | Stealth and Fully-Laden Drug Carriers: Self-Assembled Nanogels Encapsulated with EGCG and siRNA |
| Peptide | tumor-homing CPP (PEGA-pVEC) |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | |
| Formulation Format | self-assembled nanogel (siRNA/EGCG/protamine/HA) + CPP |
| Formulation Components | siRNA + EGCG + protamine sulfate + HA + tumor-homing CPP |
| Size Nm | 80.00 |
| Zeta Mv | 20.00 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | BALB/c nude mice; MDA-MB-231 xenograft |
| Administration Route | intravenous (tail vein) |
| Output Type | tumor growth inhibition |
| Output Value | Strong tumor suppression; increased TUNEL apoptosis; CTGF pathway downregulated |
| Output Units | |
| Output Notes | Nanogel@peptide superior to EGCG or nanogel alone |
| Toxicity Notes | No significant weight loss or organ toxicity |
| Curation Notes |